0001213900-23-081824.txt : 20231031 0001213900-23-081824.hdr.sgml : 20231031 20231031162551 ACCESSION NUMBER: 0001213900-23-081824 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20231030 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231031 DATE AS OF CHANGE: 20231031 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Inmune Bio, Inc. CENTRAL INDEX KEY: 0001711754 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 475205835 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38793 FILM NUMBER: 231364865 BUSINESS ADDRESS: STREET 1: 225 NE MIZNER BLVD, SUITE 640 CITY: BOCA RATON STATE: FL ZIP: 33432 BUSINESS PHONE: 8589643720 MAIL ADDRESS: STREET 1: 225 NE MIZNER BLVD, SUITE 640 CITY: BOCA RATON STATE: FL ZIP: 33432 8-K 1 ea187555-8k_inmune.htm CURRENT REPORT
0001711754 false FL 0001711754 2023-10-30 2023-10-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 30, 2023

 

INMUNE BIO INC.
(Exact name of registrant as specified in charter)

 

Nevada   001-38793   47-5205835
(State or other jurisdiction   (Commission File Number)   (IRS Employer
of incorporation)       Identification No.)

 

225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432

(Address of Principal Executive Offices) (Zip Code)

 

(858) 964 3720

(Registrant’s Telephone Number, Including Area Code)

 

Not Applicable

(Former Name or Former Address, If Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per shares   INMB   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

  

Item 7.01. Regulation FD Disclosure.

 

On October 31, 2023, INmune Bio Inc. (the “Company”), issued a press release announcing that the Company received an International Search Report and Written Opinion communicating possession of novelty, inventive step, and industrial applicability in all claims pending in an international patent application covering, among other things, its proprietary cell line, INB16, and the INKmune™ therapeutic composition. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

The information furnished in this Item 7.01 and exhibit 99.1 in Item 9.01 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 8.01. Other Events.

 

On October 30, 2023, the Company issued a press release announcing that in collaboration with the Company, Roxana Schillaci Ph.D. of Instituto de Biología y Medicina Experimental in Buenos Aries, Argentina will be presenting data on the use of INB03, a dominant-negative inhibitor of soluble TNF in the treatment of high-risk MUC4 expressing HER2+ breast cancer at the 38th annual Society of Immunotherapy in San Diego, California which runs from November 1-4, 2023. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

  

Item 9.01 Financial statements and Exhibits

 

(d) Exhibits.

 

99.1   Press Release dated October 31, 2023
99.2   Press Release dated October 30, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INMUNE BIO INC.
   
Date: October 31, 2023 By: /s/ David Moss
    David Moss
    Chief Financial Officer

 

 

2

 

 EX-99.1 2 ea187555ex99-1_inmune.htm PRESS RELEASE DATED OCTOBER 31, 2023

Exhibit 99.1

 

 

INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority

 

INmune Bio receives International Search Report and Written Opinion communicating possession of novelty, inventive step, and industrial applicability in all claims pending in an international patent application covering, among other things, its proprietary cell line, INB16, and the INKmune™ therapeutic composition.

 

Boca Raton, Florida, Oct. 31, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced an update regarding the company’s patent covering its proprietary cell line, “INB16”, as well as the therapeutic composition comprising replication-incompetent INB16 cells known as “INKmune™” and methods of treating cancer by administering INKmune™, with a goal of achieving in vivo priming of natural killer (NK) cells to enhance the ability of a patient’s own NK-cells to effect cancer surveillance, recognition, and killing.

 

In the written opinion for the international patent application titled, “HUMAN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CELL LINE & APPLICATIONS FOR TREATING CANCER,” an examiner from the International Search Authority at the United States Patent & Trademark Office, authorized by the World Intellectual Property Organization under the Patent Cooperation Treaty, issued a favorable patentability opinion with respect to novelty, inventive step and industrial applicability of all claims and concluding that the application contains patentable subject matter. The application discloses and claims the novel INB16 cell line on deposit with the American Type Culture Collection, as well as compositions comprising replication incompetent INB16 cells (“INKmune™”) and methods of treating cancer in patients by administering INKmune™.

 

“Patents covering novel cell lines are somewhat rare in practice and form a very small number of total patents issued,” said Joshua Schoonover, Esq., in-house General Counsel for the Company. “The company is exploring several potential commercial applications of the INB16 cell line, including uses in cancer research, as well as therapeutic uses, such as applications for treating various cancer indications, or for enhancing other NK cell products to gain advantages, such as improved avidity or memory-like functions.”

 

The Company intends to leverage the favorable written opinion under the patent prosecution highway, a program offered by the USPTO, EPO and other participating patent offices to accelerate examination and ultimately patent issuance for inventions receiving favorable opinions received from certain patent authorities, including WIPO.

 

INB16 is a tumor cell line which is relatively insensitive to killing by natural killer (NK) cells from healthy donors and from patients. However, it carries molecules on its surface which bind to critical activating ligands on resting NK (rNK) cells and, when an rNK cell binds to INB16 the rNK becomes primed by the activating ligands. One of the key molecules on the INB16 surface is called CD15 and this binds to a ligand on rNK cells called CD2. Virtually all rNK in the blood express CD2. The Company has shown that this CD15-CD2 interaction is critical and has further mapped the intracellular signaling cascade that it activates. During the next 16 hours after INB16 binding, the rNK becomes “primed” to form what is called a “tumor-primed NK cell” – TpNK. These TpNK have the characteristics of memory-like NK cells described by other groups and which are produced in the lab by priming with a cocktail of inflammatory cytokines (IL12/15/18). TpNK are a type of mlNK and can kill tumor cells that are resistant to rNK cell-killing. This means that they can kill a wide range of clinically relevant cancers and leukemias. In addition, the Company’s in vitro data shows that TpNK cells are able to overcome the immunosuppression of hypoxia and regulatory cells in an active Tumor Microenvironment of solid tumors. The Company is extending these findings to show that INKmune-primed NK cells also overcome immunosuppressive cytokines in the TME as a result of the NK differentiation into a memory-like cell.

 

While INB16 can generate TpNK cells in vitro, it cannot be used to treat NK cells in the blood of patients without being treated to prevent it from further proliferation. To overcome this, the Company uses novel methods to make the INB16 unable to replicate and created a “replication-incompetent cell,” which forms a basis of the biologic called “INKmune™.” The Company has safely treated five patients with hematological cancers and shown that INKmune™ treatment converts patient’s normal resting NK cells into potent memory-like NK cells much like those that can be produced in vitro. More patients are awaiting trial enrolment. Administration of INKmune may be the only way to create mlNK in vivo because the cytokine cocktail used by others would be too toxic to use as a direct treatment.

 

The Company opened an IND for a US trial of INKmune™ in metastatic castration-resistant prostate cancer. The first site will be initiated in the second week of November, meaning that efforts are ahead of schedule for the planned first patient treatment in this quarter. At least one other site is expected to be opened before the end of the year. A clinical batch of INKmune™ has been manufactured for the first US cohort and is ready to be shipped to a distribution center. Patients at each dose level will receive all three doses of INKmune™ as an out-patient treatment during the six-month trial. Two markers of INKmune™ efficacy will be measured – immunologic activation and therapeutic efficacy as a measure tumor response to INKmune™ therapy, using traditional biomarkers of prostate cancer tumor burden (progression-free survival, changes in blood PSA level, and tumor burden measured by bone and CT scan).

 

 

 

 

Acronyms:

 

ATCC: American Type Culture Collection
EPO: European Patent Office
mlNK: memory-like NK cells
NK cell: Natural Killer cell
TME: Tumor Microenvirnoment
TpNK: Tumor Primed NK Cell
USPTO: United States Patent & Trademark Office
WIPO: World Intellectual Property Organization

 

About INKMUNE

 

INKmune™ is an investigational biologic substrate that can be administered to a patient for in vivo priming of a patient’s own NK cells. Cancerous cells occur regularly during the lifetime of a healthy individual, but the individual’s NK cells generally surveil, recognize, and often kill these cancerous cells before they become a problem. Sometimes, however, cancer cells can downregulate protein signals or otherwise hide from NK cells, effectively evading killing. INKmune™, a therapeutic composition comprising replication incompetent INB16 cells, is modified to prevent proliferation in a patient’s body, but provides certain signals necessary to stimulate or “prime” NK cells so that they can achieve enhanced surveillance, recognition and killing of cancer cells in a patient. INKmune™ is stable at -80oC and is delivered by a simple IV infusion. The INKmune™:NK interaction ligates multiple activating and co-stimulatory molecules on the NK cell and enhances its avidity of binding to tumor cells; notably those resistant to normal NK-mediated lysis. Tumor-primed NK (TpNK) cells can lyse a wide variety of NK-resistant tumors including leukemias, lymphomas, myeloma and solid tumors including prostate, renal cell, ovarian, nasopharyngeal, lung and breast cancer. INKmune™ therapy does not require any type of conditioning, pre-medication or cytokine support.

 

About INmune Bio Inc.

 

INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03™), Early Alzheimer’s disease, and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune™ developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic and solid tumor malignancies, and chronic inflammation. To learn more, please visit www.inmunebio.com.

 

Forward Looking Statements

 

Clinical trials are in the early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595 (XPro™), and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

 

INmune Bio Contact:

 

David Moss, CFO
(858) 964-3720
info@inmunenbio.com

 

Investor Contact:
Jason Nelson, Core IR
(516) 842-9614 x-823

 

 

 

 

 EX-99.2 3 ea187555ex99-2_inmune.htm PRESS RELEASE DATED OCTOBER 30, 2023

Exhibit 99.2

 

 

INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα

 

SIRP-CD47 is an innate immune checkpoint known as the “don’t eat me” signal. INB03 downregulates expression of SIRPα on macrophages promote increased cancer cell death by antibody dependent cellular phagocytosis (ADCP).

 

Boca Raton, Florida, Oct. 30, 2023 (GLOBE NEWSWIRE) --   INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is presenting data on the use of INB03, a dominant-negative inhibitor of soluble TNF in the treatment of high-risk MUC4 expressing HER2+ breast cancer. Roxana Schillaci Ph.D. of Instituto de Biología y Medicina Experimental in Buenos Aries, Argentina, will present her work at the 38th annual Society of Immunotherapy in San Diego, California which runs from November 1-4.

 

The poster entitled “INB03: a new immune checkpoint inhibitor that reprograms polarization and promotes ADCP in human macrophages,” shows that INB03 is an innate immune checkpoint inhibitor working through the SIRPα-CD47 pathway to promote ADCP. SIRPα is a surface protein expressed by macrophages that binds to CD47 expressed by tumor cells. SIRPα-CD47 is known as the “don’t eat me” signal that prevents phagocytosis of tumor cells and promotes resistance to immunotherapy. INB03 downregulates SIRPα expression to eliminate the “don’t eat me signal” and promote ADCP. Inhibition of the SIRPα-CD47 pathway has focused predominately on targeting CD47 with anti-CD47 therapeutics. Targeting SIRPα may provide differentiated pharmacokinetic, safety, and efficacy profiles.

 

“Macrophages play an important role in the control of tumors, but cancer cells have developed very efficient ways to evade attack by the patient’s immune system,” said Roxana Schillaci, Ph.D. of CONECIT and senior author of this work. “TNF promotes expression of SIRPα on macrophages that bind to CD47 on tumor cells to prevent ADCP.  Neutralization of sTNF with INB03 downregulates the expression of SIRPα to promote ADCP that should help control tumor growth and prevent resistance to immunotherapy.”

 

The research presented in the poster examines animal models and human macrophages. INB03 neutralizes sTNF, repolarizing tumor protecting M2 macrophages to M1 anti-tumor macrophages, enhances ADCP with trastuzumab, and reduces SIRPα expression. In mice with trastuzumab resistant breast cancer, INB03 treatment polarizes splenic and tumor-infiltrating macrophages to M1 type macrophages that phagocytize tumor cells and decreased immune checkpoint expression (PD-L1, TIM3, LAG3) in tumor-infiltrating CD8+ T cells.

 

RJ Tesi MD, CEO of INmune Bio, stated that, “a new therapeutic strategy for treating cancer is to improve the function of tumor-infiltrating macrophages. DN-TNF has been shown to improve macrophage phagocytosis in models of AD, MS, DMD, and cancer.” Microglia are tissue-based macrophages of the brain, while tumor macrophages are the phagocytic cells of the tumor microenvironment (TME). In disease, soluble TNF depresses macrophage phagocytic function, resulting in neurodegeneration, synaptic dysfunction, and demyelination in the brain or tumor growth and resistance to cancer immunotherapy. DN-TNF neutralizes sTNF and returns phagocytic function to normal. In neurodegenerative diseases, DN-TNF promotes microglial phagocytic function to promote remodeling and repair by decreasing neurodegeneration, improving synaptic plasticity, and promoting remyelination. In cancer, DN-TNF repolarizes immunosuppressive macrophages into tumor-killing macrophages and promotes ADCP. In both cases, normalizing phagocytic function should allow for therapeutic benefits.

 

 

 

 

Acronyms:

 

DN-TNF: Dominant-Negative Tumor Necrosis Factor
sTNF: Soluble Tumor Necrosis Factor
ADCP: Antibody Dependent Cellular Phagocytosis
SIRPα: Signal-Regulatory Protein Alpha
TME: Tumor Microenviornment
AD: Alzheimer’s Disease
MS: Multiple Scleroisis
DMD: Duchenne Muscular Dystrophy
CNS: Central Nervous System

 

About INB03

 

INB03 is a DN-TNF inhibitor that neutralizes soluble TNF (sTNF) without affecting transmembrane TNF (tmTNF) or TNF receptors. Compared to currently available non-selective TNF inhibitors, INB03 preserves the immune response to cancer by decreasing immunosuppressive cells in the TME including TAM and MDSC while promoting recruitment of anti-tumor immune cells including cytolytic CD8+ lymphocytes, NK cells and anti-tumor macrophages. INB03 has completed an open label dose-escalation Phase I trial in patients with advanced cancer. In that trial, INB03 was found to be safe and well tolerated - no dose limiting toxicity was found. INB03 decreased blood biomarkers of inflammation in patients with advanced cancer. INMB is planning a Phase II trial that uses IN03 as part of combination therapy.

 

About INmune Bio Inc.

 

INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03™), Early Alzheimer’s disease, and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune™ developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic and solid tumor malignancies, and chronic inflammation. To learn more, please visit www.inmunebio.com.

 

Forward Looking Statements

 

Clinical trials are in the early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595 (XPro™), and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

 

INmune Bio Contact:

 

David Moss, CFO
(858) 964-3720
info@inmunenbio.com

 

Investor Contact:
Jason Nelson, Core IR
(516) 842-9614 x-823

 

 

 

 

 

 EX-101.SCH 4 inmb-20231030.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 inmb-20231030_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 inmb-20231030_pre.xml XBRL PRESENTATION FILE GRAPHIC 7 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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ex99-2_001.jpg GRAPHIC begin 644 ex99-2_001.jpg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htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Oct. 30, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 30, 2023
Entity File Number 001-38793
Entity Registrant Name INMUNE BIO INC.
Entity Central Index Key 0001711754
Entity Tax Identification Number 47-5205835
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 225 NE Mizner Blvd.
Entity Address, Address Line Two Suite 640
Entity Address, City or Town Boca Raton
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33432
City Area Code 858
Local Phone Number 964 3720
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per shares
Trading Symbol INMB
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 10 ea187555-8k_inmune_htm.xml IDEA: XBRL DOCUMENT 0001711754 2023-10-30 2023-10-30 iso4217:USD shares iso4217:USD shares 0001711754 false FL 8-K 2023-10-30 INMUNE BIO INC. NV 001-38793 47-5205835 225 NE Mizner Blvd. Suite 640 Boca Raton 33432 858 964 3720 false false false false Common Stock, par value $0.001 per shares INMB NASDAQ true false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://inmunebio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea187555-8k_inmune.htm inmb-20231030.xsd inmb-20231030_lab.xml inmb-20231030_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea187555-8k_inmune.htm": { "nsprefix": "INMB", "nsuri": "http://inmunebio.com/20231030", "dts": { "inline": { "local": [ "ea187555-8k_inmune.htm" ] }, "schema": { "local": [ "inmb-20231030.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "inmb-20231030_lab.xml" ] }, "presentationLink": { "local": [ "inmb-20231030_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://inmunebio.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-10-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea187555-8k_inmune.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-10-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea187555-8k_inmune.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 18 0001213900-23-081824-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-081824-xbrl.zip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end